SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is drawing attention after a disappointing Q3 report, with an unexpected loss, compressed margins, and reduced profit guidance weighing on shares despite strong revenue growth. Traders are split between concern about profitability and subscriber trends and optimism around international expansion, branded weight-loss drug partnerships, and potential peptide offerings.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A Q3 earnings beat, stronger-than-expected Q4 guidance and expanded buyback authorization sparked a sharp rally, but the move faded as traders focused on cautious management commentary and continued growth and margin concerns. The community is split between seeing short-squeeze potential and viewing the reversal as a warning about the business outlook and management credibility.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbines quarterly results and raised revenue outlook are driving attention, with traders pointing to strong growth and improving business momentum. The reaction is divided: bulls see a turnaround taking hold, while others focus on compressed margins, limited EBITDA improvement, debt, and accounting concerns.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention after CEO Jensen Huang acknowledged a relationship with a Megaspeed executive reportedly suspected of Chinese intelligence ties, prompting a board investigation and shareholder lawsuit. Traders are split between treating the controversy as a temporary distraction and buying the dip based on Nvidias AI-chip business, and worrying about governance, regulatory fallout or Huangs future as CEO; the stocks weakness during a broader chip rally has intensified the debate.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs quarterly results and AI/HPC pivot are driving attention: earnings beat, but revenue missed amid weaker Bitcoin prices, while the company highlighted a GPU-services contract, debt reduction and a share-repurchase authorization. Traders are divided between welcoming these steps as evidence of progress and questioning the quality of reported earnings and the lack of signed tenants for its broader data-center plans.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,203,846.69715353. The last known price of Ethereum is 2,121.02700944 USD and is down -0.91 over the last 24 hours. It is currently trading on 14303 active market(s) with $13,174,532,202.61 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereums sharp weakness amid a broader crypto selloffand its underperformance versus stocks and, at times, Bitcoinis driving discussion, with traders pointing to liquidations and fund outflows while debating whether the decline is nearing a bottom. Bears expect further losses, while some holders are buying dips and arguing for a rebound; proposed explanations such as macro and political concerns remain speculative.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs Q3 results are driving attention: revenue, backlog and forward guidance beat expectations, while the EPS miss and Neutrons delay to no earlier than 2027 weighed on the report. Traders are split between bullish views that demand and contracts support the long-term story and concerns about losses, execution risk and the post-earnings pullback.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly report showed strong BRIUMVI growth and a higher full-year revenue outlook, driving attention to the drugs commercial momentum. Traders were broadly bullish despite a sharp post-report pullback and recovery, while many pointed to the upcoming subcutaneous BRIUMVI Phase 3 readout as the next key catalyst; buyout and short-squeeze talk remained speculative.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidentals Q3 earnings beat on adjusted EPS, but revenue slightly missed expectations and the stock has struggled to respond. Traders are weighing the strong results and debt reduction against softer oil prices, weaker sequential cash flow and lower production, with some also criticizing the lack of buybacks.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Twos quarterly report showed softer-than-expected bookings and an unchanged outlook, while management described GTA VI preorders as unprecedented ahead of the planned launch. Traders are split between concern about cautious guidance and weaker performance outside GTA, and optimism that the blockbuster release and future online spending can drive growth.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress

Alkermes plc (Nasdaq: ALKS) today announced plans to present data from across its psychiatry and sleep medicine portfolios at the Neuroscience Education Institute (NEI) Fall Congress, taking place Nov. 5-8, 2026 in Colorado Springs, Colo. The company will present data related to LYBALVI (olanzapine...

Alkermes to Present at Upcoming Investor Conferences

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2026 Healthcare Conference Date/Time: Fireside chat on Tuesday, Nov. 10, 2026 at 10:40 a.m. ET (3:40 p.m. GMT) Jefferies Global Healthcare Conference in London Date/Time...

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates

Alkermes (ALKS) delivered earnings and revenue surprises of +212.50% and +3.05%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Alkermes plc Reports Third Quarter 2026 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and presentation, please visit the companys investor relations website at https://investor.alkermes.com. Alkermes will host a...

Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)

Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in adult participants with major depressive disorder (MDD). ALKS 7290 is the companys investigational orexin 2 receptor (OX2R...

Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of +642.47% and +0.63%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline

Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes to Report Third Quarter Financial Results on November 3, 2026

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the companys third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes...

Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>In a mid-stage study, alixorexton demonstrated statistically significant, clinically meaningful and dose-dependent improvements from baseline compared to placebo in wakefulness.</li><li>RBC Capital said the Lilly-Centessa deal highlights large pharma interest in the sleep space and "underscores what could likely be a large indication," which is "favorable" for Alkermes.</li><li>Leerink, who has a ‘Market Perform’ rating on Alkermes shares, opined that the stock could attract interest from large pharma companies seeking a presence in sleep disorders.</li></ul>Shares of Alkermes Plc (ALKS) rallied 15% on Tuesday after pharmaceutical giant Eli Lilly and Company reached an agreement to acquire its peer Centessa for up to $7.8 billion.Centessa is developing a pipeline of orexin receptor 2 (OX2R) agonists to treat excessive daytime sleepiness and disorders of impaired wakefulness. Its lead investigational candidate cleminorexton is under development to treat narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.Alkermes, meanwhile, is also developing an orexin 2 receptor for narcolepsy called alixorexton. In a mid-stage study, alixorexton demonstrated statistically significant, clinically meaningful and dose-dependent improvements from baseline compared to placebo in wakefulness. Alkermes plans to initiate the alixorexton narcolepsy global phase 3 program in early 2026.<h2 class="st-heading-2">Wall Street Weighs In</h2>RBC Capital said the Lilly-Centessa deal highlights large pharma interest in the sleep space and "underscores what could likely be a large indication," which is "favorable" for Alkermes. The firm, which thinks Alkermes' current share price is undervaluing the orexin program alone given comps, notwithstanding the profitable core business, has an ‘Outperform’ rating and $45 price target on the shares.Leerink, who has a ‘Market Perform’ rating on Alkermes shares, opined that the stock could attract interest from large pharma companies seeking a presence in sleep disorders.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ALKS stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.<a href="https://stocktwits.com/symbol/ALKS">ALKS stock</a> has gained 5% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-rallies-in-anticipation-of-upbeat-q1-delivery-numbers-after-america-expansion-efforts/cZE5cWMRIVp">Nio Stock Rallies In Anticipation Of Upbeat Q1 Delivery Numbers After America Expansion Efforts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alkermes logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Shares of Alkermes Plc (ALKS) rallied 15% on Tuesday after pharmaceutical giant Eli Lilly and Company reached an agreement to acquire its peer Centessa for up to $7.8 billion.

Alkermes, like Centessa, is also developing an orexin 2 receptor for narcolepsy called alixorexton.


Centessa Pharmaceuticals PLC - ADR

Lilly(Eli) & Co

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Current Price	$46.17
Prev Close	$45.90
Open	$46.10
Dividend Yield	0.00%
50-Day Moving Average	$43.68
Beta	0.64
Avg. Volume	1.94M
PE Ratio	-3,370.07

52-Week High	$55.67
52-Week Low	$27.00
Market Capitalization	$7.71B
EPS (Annual)	$1.43
Price to Book	4.16
Revenue Per Employee	$719,950.73

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALKS Fundamentals